Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red cell volume transfused (total) · participants undergoing surgery
1 finding from 1 review
Number of participants receiving a red cell transfusion (total) · participants undergoing surgery
It is very uncertain whether DDAVP changes number of participants receiving a red cell transfusion (total) compared with tranexamic acid (very low certainty).
1 finding from 1 review
Blood loss (total) · participants undergoing surgery
1 finding from 1 review
All‐cause mortality · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery
It is very uncertain whether DDAVP changes all thrombotic events (including myocardial infarction, ischaemic… compared with tranexamic acid (very low certainty).
1 finding from 1 review
Quality of life · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Blood transfusion · Percutaneous nephrolithotomy
Topical TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in thromboembolic events compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Adverse event · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in adverse event compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in major surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Minor surgical complications · Percutaneous nephrolithotomy
Topical TXA may leads to lower minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Unplanned hospitalizations or readmissions · Percutaneous nephrolithotomy
1 finding from 1 review
Length of hospital stay · Percutaneous nephrolithotomy
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
1 finding from 1 review
Adverse events · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in adverse events compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review